Background. Effectiveness of human papillomavirus (HPV) vaccines in the context of both guidelines, which recommend vaccination at 14 years and modest vaccine coverage, is poorly documented.
Human papillomavirus vaccination coverage at a 3-dose regimen decreased in France from 28% in 2012 to 19% in 2014, according to the National Health Insurance Information database, probably due to negative media coverage [8] . We decided to evaluate direct vaccine effectiveness against HPV vaccine genotypes using individually identifiable information on vaccination status [9] . This study was conducted to compare infection with HPV vaccine genotypes in specimens obtained from vaccinated versus unvaccinated sexually active young females undergoing screening for Chlamydia trachomatis. We report findings on vaccine effectiveness based on sexual behavior and prevalence of HPV genotypes according to individual HPV vaccine status.
MATERIALS AND METHODS
We used cervical samples collected for C. trachomatis screening in 9 sexually transmitted disease (STD) clinics across France. In France, C. trachomatis testing is recommended for all sexually active women following change in sexual partner and is free of charge for those aged <25 years in STD clinics. The HPV analysis was performed on the residual material that remained after DNA extraction and analysis for C. trachomatis. All samples were anonymized. The Ethical Review board Ile de France IV approved the protocol and decided that only verbal informed consent was required.
Recruitment and Sample Collection
Participants were recruited from June 6, 2014, to March 25, 2015 , among women aged 18-25 years. An interviewer-administered questionnaire was used to obtain data about the participant's age/date of birth, age/year at sexual debut, number of sexual partners in the past 12 months. Result of the C. trachomatis test was also collected. Participants either self-reported their HPV vaccination status (vaccinated or not, unknown status) or provided their immunization record. In this case, dates of injection of each dose (1) (2) (3) were recorded. If they did not bring their immunization record at enrollment, they were asked to bring it to their follow-up visit when they received their C. trachomatis test result. Anonymous files containing data collected at each STD clinic were sent to the HPV National Reference Centre (HPV NRC) at the Pasteur Institute, independently of the specimen. Residual self-collected cervical specimens submitted for chlamydia screening were collected from women who verbally consented to participate in the study. These were stored for <30 days at room temperature and shipped to the HPV NRC.
Sample Size Calculation
The sample size was determined by power analysis calculation. With a vaccine coverage evaluated at 30% among women aged 17 years in 2014 [8] , a decrease by 60% of vaccine-type HPV after vaccine introduction [10] , and a 90% power to assess a lower limit of 60% of the 95% confidence interval (CI) of the vaccine efficacy, we estimated that 3500 women, including 2400 unvaccinated and 1100 vaccinated needed to be enrolled (95% CI = 57.5-74.25).
Human Papillomavirus DNA genotyping
All sample processing and HPV DNA genotyping was performed at the HPV NRC. Cervical specimens were tested for HPV DNA using the PapilloCheck test system. The assay identifies 13 high-risk (HR) HPV (HPV 16, 18, 31, 33, 35, 39, 45, 51,  52, 56, 58, 59 , and 68), 5 possibly oncogenic HPV (HPV 53, 66, 70, 73, and 82), and 6 HPV considered as low-risk types (HPV 6, 11, 40, 42, 43, and 44/55). The assay uses multiplex polymerase chain reaction (PCR) with fluorescent primers to amplify a DNA fragment of approximately 350 nucleotides within the E1 open reading frame of the HPV genome. Amplification of an internal HPV template present in the PCR mastermix generates a signal on the PCR control spot on the chip. In addition, an internal PCR control that targets a region within the human ADAT-1 gene (adenosine deaminase tRNA specific 1) is used to assess cellularity. A valid result was defined as one that passed all the internal controls.
Statistical Analysis
Vaccination status was considered as (1) [11] ). We also evaluated the prevalence of 5 additional types targeted by the 9-valent HPV vaccine (HPV types 31, 33, 45, 52, and 58). We compared the HPV prevalence according to vaccination status and produced the corresponding P values using χ 2 tests.
To identify the characteristics associated with vaccine type prevalence, we performed univariable analysis of characteristics and calculated associated unadjusted prevalence ratios (PRs), their 95% confidence intervals, and P values assuming a binomial distribution. The following factors were assessed: age at enrollment, age at first sexual encounter, HPV vaccine status, C. trachomatis test result, and number of male partners in the last 12 months. Variables with P < .25 in the univariable analysis were considered for inclusion in a multivariable log-binomial regression model to obtain the adjusted prevalence ratios (aPRs).
Vaccine effectiveness (VE) was defined as (1−RR, risk ratio) × 100, with RR = P vac /P unv , P vac being the prevalence of HPV genotypes in confirmed vaccinated women (defined as ≥1 dose) and P unv being the prevalence of infection in unvaccinated women [9] . Vaccine effectiveness was calculated for infection with HPV 6, 11, 16, and 18 and HPV 31, 33, and 45. Vaccine effectiveness was reported with 95% confidence interval. Vaccine effectiveness was similarly assessed in women self-reporting vaccination. The analyses were conducted using STATA SE 13.1.
RESULTS
Of 4243 specimens received for HPV DNA testing, 4039 were tested, and 4024 had a valid result. Of these, complete data or HPV vaccine status related to the participant's specimen were missing in the database sent from the STD clinic in 151 and 86 cases, respectively, or revealed exclusion criteria related to age (50 cases), and 1 woman refused to participate in the study, leaving 3736 eligible women for analysis ( Figure 1 ).
Confirmed vaccination status according to vaccination record was available for 822 women and included 750 fully and 72 partially vaccinated. A total of 1021 participants self-reported they were vaccinated, and 1893 were unvaccinated.
Demographic and behavioral characteristics of the women are presented in Table 1 . Among vaccinated women who provided their immunization book, approximately 90% received all 3 doses of the vaccine. Among women with confirmed vaccination status, vaccination history differed according to the number of doses: fully vaccinated women were younger than partially vaccinated at first dose administration by a mean of 1 year (16.0 vs 17.3 years; P < .0001), and 87.2% of them initiated vaccination before sexual debut versus 72.2% of their counterparts (P < .0001). The number of sexual partners in the 12 months before the C. trachomatis test was only available for 2592 participant women. Behavioral characteristics, including mean age at first sexual encounter, mean number of male partners in the preceding 12 months, and positive C. trachomatis test result did not differ according to vaccination status (Table 1) .
Adjusted vaccine effectiveness for fully/partly vaccinated women with confirmed vaccination status compared with unvaccinated women was 95.93% (95% CI = 90.22%-98.32%) and 38.37% (95% CI = 12.68%-56.51%) against HPV 6, 11, 16, and 18 and against HPV 31, 33, and 45, respectively. We also evaluated VE among women who self-reported that they were vaccinated and found VE at 88.25% (95% CI = 81.19%-92.66%) and 41.24% (95% CI = 18.55%-57.01%) against vaccine and cross-reactive types, respectively ( Table 2) . Table 3 presents the crude prevalence of vaccine and cross-reactive HPV types according to vaccine status. The prevalence of vaccine types 6, 11, 16, and 18 was significantly lower in confirmed vaccinated (0.61%) than in unvaccinated participants (15.0%; P < .0001). Among women who self-reported vaccination, prevalence was 3 times higher, although not significantly, than among women with vaccination confirmed from immunization book (1.76%) but 8 times lower than in unvaccinated women (P < .0001). Among the 822 women with confirmed vaccination, vaccine types were detected in 5: only 1 had HPV 18, whereas 3 had HPV 6. HPV 18 was detected in a woman fully vaccinated after sexual debut who had only 1 sexual partner in the last 12 months and a negative C. trachomatis test. Human papillomavirus 6 was detected in 2 women who had been fully vaccinated before sexual debut and in 1 partly vaccinated after sexual debut (1 dose). The fifth patient received complete vaccination at sexual debut and had multiple infection with HPV 11, 42, 51, 52, 53, 59, and 73. The prevalence of HPV 31, 33, and 45 (cross-reactive HPV types) was significantly lower among confirmed vaccinated (4.62%; 95% CI = 3.29%-6.29%) and self-reported vaccinated (4.41%; 95% CI = 3.23%-5.85%) than among unvaccinated women (7.50%; 95% CI = 6.35%-8.78%; P < .0001). Compared with unvaccinated women, any HR HPV and HPV 31, 33, 45, 52, and 58 prevalence was significantly lower among those fully vaccinated (41.89% vs 31.51%, P < .0001; and 15.16% vs 11.56%, P = .01, respectively).
Results of univariable and multivariable analyses of factors associated with vaccine-type prevalence are presented in Table 4 . In the multivariable analysis, factors associated with prevalent HPV vaccine types were being unvaccinated compared with fully vaccinated (aPR = 24.81; 95% CI = 7.98-77.20, P < .00001), a positive C. trachomatis test result compared with negative (aPR = 1.46; 95% CI = 1.03-2.07; P = .03), and having had >4 male sex partners in the preceding 12 months (aPR = 1.51; 95% CI = 1.11-2.06; P = .0002). Compared with fully vaccinated women, partially vaccinated women had a higher, although not significantly, adjusted prevalence ratio of vaccine types (aPR = 3.01; 95% CI = 0.32-28.72); on the other hand, adjusted prevalence ratio was significantly increased among women self-reporting vaccination (aPR = 3.99; 95% CI = 1.18-13.54). Age at enrollment and at first sexual encounter were not significant.
DISCUSSION
Our study demonstrated a 95.93% vaccine effectiveness against vaccine-targeted HPV types 6, 11, 16, and 18 in sexually active young women, on average 6 years after vaccination who attended a STD clinic for C. trachomatis test following partner change. In our population from the vaccine era, >90% of women with a confirmed vaccination history completed the 3-dose series. Factors associated with prevalent vaccine types in multivariate analysis were vaccine status, a positive C. trachomatis test, and >4 partners in the last 12 months. Vaccinated women had also a lower prevalence of cross-reactive genotypes than unvaccinated women (VE = 38.37%).
The significant protection against infection with HPV 6, 11, 16, and 18 types observed among our vaccinated participants is comparable with vaccine efficacy against persistent infections reported in per-protocol analysis from randomized control trials and much higher than that observed in intentionto-treat analysis [12] . This is consistent with the fact that the characteristics of our vaccinated population were close to those of baseline HPV-negative women included in per-protocol analysis, with 91% being fully vaccinated, 87% being vaccinated before or at sexual debut, and a mean number of <3 partners in the last 12 months. The VE we observed is also similar to the VE against vaccine types reported in a large body of observational studies aimed at evaluating real-life benefit [1] . A high vaccine effectiveness, at 89%, was observed in a nationally representative population of sexually active females aged 14-24 years who received at least 1 series in the United States [13] . In Australia, Tabrizi et al reported on an adjusted VE against vaccine types 6, 11, 16, and 18 of 86% for fully vaccinated women within the postimplementation era [14] Among vaccinated women, VE against HPV types 31, 33, and 45, genetically related to vaccine types, was 38%, suggesting a potential additional benefit of the vaccine [14] . However, this benefit is probably weak because the vaccine efficacy estimate for these genotypes was low in the intention-to-treat analyses of the quadrivalent vaccine clinical trials and no significant temporal changes in their prevalence were observed in studies comparing prevalence rates in the pre-and postvaccination eras Abbreviations: aPR, adjusted prevalence ratio; CI, confidence interval; HPV, human papillomavirus; PR, prevalence ratio.
a In the multivariable model, all variables with P < .25 in univariable model were selected. Then, a multivariable log-binomial regression model was used to obtain the adjusted prevalence ratios. [13, 4, 15, 16] . We also examined prevalence of the 5 additional HR types in the 9-valent vaccine to provide a baseline before potential introduction of this vaccine in France and observed a borderline statistically significant difference in prevalence in confirmed vaccinated and unvaccinated women (P = .01), mainly related to cross-reactive types. The recent availability of the 9-valent vaccine, expected to provide excellent protection against infection with these genotypes [17] , raises the question of how to complete an immunization course among girls who have already been vaccinated with the quadrivalent (or bivalent) vaccine [18] . As suggested by Vandamme et al, this question should be addressed on an individual level because there is insufficient evidence at this time to recommend reimmunization at a country level with the 9-valent vaccine in subjects who completed the full immunization course with the 2-valent or 4-valent vaccine [18] . Contrary to the assumption that many young sexually active females attending a STD clinic would be infected with HPV, HR HPV DNA was only detected in one third of samples. This might be related to the fact that our study population had already been sexually active for about 5 years, whereas infection appears to be acquired, for a high proportion of women, at first sexual intercourse [19] . In common with other studies [20] , HR-HPV, as well as vaccine-type DNA detection, appeared to be highly related to sexual activity, as assessed by multiple sexual partners and presence of C. trachomatis infection. Induction of squamous metaplasia associated with C. trachomatis infection has been suggested as providing a possible way of infection with HPV, and C. trachomatis has been shown to play a cofactor role in the development of HPV-associated cervical neoplasia, possibly by prolonging the duration of HPV infection [21] . Among the unvaccinated population, 85% were DNA-negative to vaccine types. Their unvaccinated status can be assumed because it was confirmed in 21% of them from immunization record. Because we did not investigate serological status for antibody to HPV vaccine types, we were not able to identify those who were naive among them and may benefit from vaccine from those who had been infected and had already cleared their infection.
It has been hypothesized that sexual disinhibition could occur after HPV vaccination [22] . This was not the case in a cross-sectional survey conducted in the United Kingdom in women aged 16 to 18 years, where neither being offered the HPV vaccine nor receiving it affected sexual behavior [23] . Bednarczyk et al observed similar results in the United States after adolescent HPV vaccination at age range 11-12 years [22] . Concordant with these results, we did not observe any difference in median age at sexual debut, number of sexual partners, in C. trachomatis status according to vaccine status.
Evaluating the history of HPV vaccination is challenging for monitoring vaccine uptake and effectiveness. In France, each newborn receives a child health book at birth, which is intended to be kept for life. Vaccinations are recorded in it upon administration. Many participants in the study explained that they had not taken their child health book with them on leaving the family home, were thus unable to provide it, and self-reported their vaccination status during the pretest interview. That the observed prevalence of vaccine-type HPV in women self-reporting vaccination is much closer to that of the confirmed vaccinated than the unvaccinated suggests that most of them had indeed been vaccinated. In fact, data from the Connecticut HPV-Impact Working Group show that the concordance between medical record and interview for obtaining HPV vaccination history was high at 83% [24] . Similar concurrence between self-reported and administratively or physician-validated status was also reported in recent surveys performed in Australia and in Belgium [25, 26] . This might be related to the fact that vaccination is frequently painful, has occurred in the recent past, mostly within 5-6 years, and is highly publicized, making it easier for young women to remember. Assessment of vaccination history will be of interest to evaluate vaccine programs when vaccinated women will initiate cervical cancer screening.
Our assessment has several limitations. First, our population was sexually active women attending a STD clinic for C. trachomatis on partner change and may not be representative of women opportunistically vaccinated in terms of risk behavior. In fact, the overall prevalence of C. trachomatis was 9%, similar to the national rate reported in STD clinics, but in contrast with the 3.2% reported among women aged 18-25 years [27] . The changes we noted might be more marked in a population at lower risk because their risk of acquisition of HPV would be lower [28] . The recent lowering of the age at vaccine initiation could also increase the differences in demographics between those vaccinated versus unvaccinated. On the other hand, our study population has a median age at first sexual encounter very similar to that of the general population (17.0-18.0 versus 17.6) [29] .
Second, vaccine effectiveness was evaluated at the individual level, and we could not explore herd immunity suggested in several population-based studies [7, 30] , which would increase the vaccine effectiveness compared with the individual-level efficacy. Nevertheless, herd immunity is probably more evident in countries with high vaccine coverage than in countries with low levels [7, 14] , suggesting that in the latter, population-level impact only depends on population coverage, as well as direct vaccine effectiveness. Thus, our study design did not allow us to assess changes in HPV ecology at the entire population level.
In conclusion, the high effectiveness of prophylactic vaccines as demonstrated in this study underlines the benefit of vaccination for women. High vaccine coverage could result in dramatic decline in prevalence of infection with genotypes responsible for 70% of cervical cancers and 56% of precancerous lesions [31] and translate into a reduction in cervical disease with a subsequent fall in treatment and potentially negative obstetric outcomes.
The impact of HPV vaccination depends on vaccine coverage. A shift toward implementation of school-based vaccine delivery programs might contributes to its increase. The availability of the 9-valent vaccine in the near future could be a good opportunity for such a change in vaccination policy.
Notes

